Risk-adapted approach to prostate cancer screening
Mass prostatic specific antigen (PSA) testing (population-based PSA screening) has remained controversial, nevertheless there are men cohorts likely to benefit from PSA screening. Heritable factors contribute to 60 % risk for developing familial prostate cancer. Despite the fact that its clinical ap...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2018-07-01
|
Series: | Onkourologiâ |
Subjects: | |
Online Access: | https://oncourology.abvpress.ru/oncur/article/view/832 |
id |
doaj-3e3c7d0ad66340b280a6cf41a22813a7 |
---|---|
record_format |
Article |
spelling |
doaj-3e3c7d0ad66340b280a6cf41a22813a72021-07-29T08:41:43ZrusABV-pressOnkourologiâ 1726-97761996-18122018-07-0114210912110.17650/1726-9776-2018-14-2-109-121771Risk-adapted approach to prostate cancer screeningA. A. Kirichek0L. N. Lyubchenko1V. B. Matveev2N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaMass prostatic specific antigen (PSA) testing (population-based PSA screening) has remained controversial, nevertheless there are men cohorts likely to benefit from PSA screening. Heritable factors contribute to 60 % risk for developing familial prostate cancer. Despite the fact that its clinical application is challenging due to polygenic inheritance, advances in new generation sequencing technologies permit identifying highly penetrant germline mutations in genes BRCA1, BRCA2, CHEK2, HOXB13 and MMR associated with tremendous increase in risk of developing the prostate cancer. Several germline mutations are associated with clinically aggressiveness of disease and shortened survival. Targeted screening that is based on family history and genomic aberrations should be the next step towards the precision medicine. Men at elevated risk should been performed for early detection are those with familiar history of prostate cancer, or BRCA1, BRCA2, CHEK2, HOXB13 and MMR pathogenic germline mutation carriers, or first line relatives diagnosed with certain types of cancer. Systematic PSA testing in 1–2 years among germline mutation carriers men beginning at age 45 years would contribute to increase in early detection of localized prostate cancer resulting in more chance of curative treatment and improve survival rateshttps://oncourology.abvpress.ru/oncur/article/view/832prostate cancerfamily historygermline mutationbrca1brca2hoxb13chek2lynch syndrometargeted screening |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
A. A. Kirichek L. N. Lyubchenko V. B. Matveev |
spellingShingle |
A. A. Kirichek L. N. Lyubchenko V. B. Matveev Risk-adapted approach to prostate cancer screening Onkourologiâ prostate cancer family history germline mutation brca1 brca2 hoxb13 chek2 lynch syndrome targeted screening |
author_facet |
A. A. Kirichek L. N. Lyubchenko V. B. Matveev |
author_sort |
A. A. Kirichek |
title |
Risk-adapted approach to prostate cancer screening |
title_short |
Risk-adapted approach to prostate cancer screening |
title_full |
Risk-adapted approach to prostate cancer screening |
title_fullStr |
Risk-adapted approach to prostate cancer screening |
title_full_unstemmed |
Risk-adapted approach to prostate cancer screening |
title_sort |
risk-adapted approach to prostate cancer screening |
publisher |
ABV-press |
series |
Onkourologiâ |
issn |
1726-9776 1996-1812 |
publishDate |
2018-07-01 |
description |
Mass prostatic specific antigen (PSA) testing (population-based PSA screening) has remained controversial, nevertheless there are men cohorts likely to benefit from PSA screening. Heritable factors contribute to 60 % risk for developing familial prostate cancer. Despite the fact that its clinical application is challenging due to polygenic inheritance, advances in new generation sequencing technologies permit identifying highly penetrant germline mutations in genes BRCA1, BRCA2, CHEK2, HOXB13 and MMR associated with tremendous increase in risk of developing the prostate cancer. Several germline mutations are associated with clinically aggressiveness of disease and shortened survival. Targeted screening that is based on family history and genomic aberrations should be the next step towards the precision medicine. Men at elevated risk should been performed for early detection are those with familiar history of prostate cancer, or BRCA1, BRCA2, CHEK2, HOXB13 and MMR pathogenic germline mutation carriers, or first line relatives diagnosed with certain types of cancer. Systematic PSA testing in 1–2 years among germline mutation carriers men beginning at age 45 years would contribute to increase in early detection of localized prostate cancer resulting in more chance of curative treatment and improve survival rates |
topic |
prostate cancer family history germline mutation brca1 brca2 hoxb13 chek2 lynch syndrome targeted screening |
url |
https://oncourology.abvpress.ru/oncur/article/view/832 |
work_keys_str_mv |
AT aakirichek riskadaptedapproachtoprostatecancerscreening AT lnlyubchenko riskadaptedapproachtoprostatecancerscreening AT vbmatveev riskadaptedapproachtoprostatecancerscreening |
_version_ |
1721252459058298880 |